Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial. At 36 weeks, patients in Cohort 9 (n=3) demonstrated a robust response…